December 3, 2020 -- GEMoaB has initiated its phase IA clinical trial with UniCAR-T prostate-specific membrane antigen (PSMA), an investigational UniCAR cellular immunotherapy, for the treatment of relapsed/refractory solid tumors expressing PSMA.
The UniCAR platform was designed to control the universal chimeric antigen receptor (CAR) T-effector cell through a rapidly switchable on/off capability. In combination with the ability to target specific tumor antigens by redirecting and activating UniCAR-T cells through soluble adapters (targeting modules), the platform offers a high degree of flexibility. The targeting modules provide antigen-specificity to activate UniCAR gene-modified T cells.
The phase IA study includes patients with late-stage PSMA-positive relapsed/refractory solid tumors such as castrate resistant prostate cancer, non-small cell lung cancer, or triple-negative breast cancer.
The study will evaluate the safety and potential efficacy of the combined application of a single dose of UniCAR-T and continuous infusion of PSMA-specific targeting modules.